The Times: The headline rate of inflation fell more than expected in November to a 10-month low – increasing expectations that the Bank of England will cut interest rates tomorrow. The
N4 Pharma plc (AIM: N4P) Partnership with University of Strathclyde’s CMAC National Facility
Collaboration combines N4 Pharma’s innovative Nuvec® delivery platform with CMAC’s world-class expertise to accelerate development and broaden therapeutic applications
Breakthrough in Targeted Cancer Treatment Sends N4 Pharma Stock Soaring
N4 Pharma PLC (AIM: N4P) shares surged after the company announced that its Nuvec® delivery system had successfully targeted non-small cell lung cancer cells in collaboration with leading US research
N4 Pharma PLC (AIM:NP4) Directorate Changes
N4 Pharma plc (AIM: N4P), the biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce the appointment of Dr
Traders Cafe with Zak Mir: Bulletin Board Heroes, Wednesday 4th December 2024
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Gold, Audioboom, Blue
N4 Pharma PLC (AIM:N4P) N4 Pharma CEO Q&A Now LIVE
N4 Pharma CEO Q&A Now LIVE
N4 Pharma PLC (AIM: N4P) Collaboration Agreement with SRI International Inc
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system designed to carry nucleotides to be developed as cancer treatments and vaccines, is delighted to
N4 Pharma PLC (AIM:N4P) Oral Delivery Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further positive update on its
Traders Cafe with Zak Mir: Bulletin Board Heroes, Monday 15th April 2024
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Gold, WTI, Asiamet,
N4 Pharma PLC (AIM:N4P) in-vitro siRNA update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to provide a further encouraging update
RNS Hotlist with Zak Mir: GENF, BOOM, YCA, ROCK, VRS, AVCT, ANGS, CYK, PXEN & N4P
Genflow Bioscience (GENF) yesterday afternoon announced two research grants totally €2.9m to develop gene therapies that increase human life spans with better health.
N4 Pharma PLC (AIM:N4P) Patent Grant
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to announce that the University of Queensland has informed